Liquidia's 2025 EPS misses analyst expectations

Liquidia

05/03/2026 11:38

Overview

Biopharmaceutical firm's YUTREPIA sales led to second consecutive profitable qtr

Company ended 2025 with $190.7 mln cash, up $33.2 mln from Q3

EPS for 2025 missed analyst expectations

Outlook

Liquidia plans to deepen prescriber adoption and grow its sales force in 2026

Company aims to expand YUTREPIA's clinical evidence through multiple new studies

Liquidia to advance L606 into pivotal trials, funded from operations

Result Drivers

YUTREPIA SALES - Strong sales of YUTREPIA contributed to second consecutive profitable quarter

PATIENT ADOPTION - Over 2,900 patients treated with YUTREPIA since launch, indicating strong market adoption

CASH POSITION - Ended 2025 with $190.7 mln in cash, an increase of $33.2 mln from Q3, reflecting financial strength

Company press release: ID:nGNX5Dc07y

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY EPS
Miss
-$0.80
-$0.76 (9 Analysts)
FY Operating Income
-$51.38 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Liquidia Corp is $49.00, about 42.5% above its March 4 closing price of $34.38

The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 19 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)